Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer
Authors:
- Bram H. GoldsteinBGBram H. Goldstein
- Mark A. RettenmaierMRMark A. Rettenmaier
- Julie MattisonJMJulie Mattison
- Cheri GrahamCGCheri Graham
- Connie L. BirkCBConnie L. Birk
- John V. BrownJBJohn V. Brown
- 30 September 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (3) , 719-724
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Dose-dense cisplatin/paclitaxelEuropean Journal of Cancer, 2002
- Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancerAnti-Cancer Drugs, 2002
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- A Phase II Trial of Intraperitoneal Cisplatin and Etoposide as Consolidation Therapy in Patients with Stage II–IV Epithelial Ovarian Cancer Following Negative Surgical AssessmentGynecologic Oncology, 1998
- Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian CancerGynecologic Oncology, 1998
- Gemcitabine in ovarian cancer: An overview of safety and efficacyEuropean Journal of Cancer, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 1994
- Creatinine Clearance: Bedside EstimateAnnals of Internal Medicine, 1973